← 返回

Polo 样激酶 4 抑制剂 CFI-400945 通过细胞周期扰动和激发抗肿瘤免疫抑制肝癌

英文原题:Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.

查看英文原题

Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.

PubMed 2023/02/17(内容时间) Hepatology Q1 · IF 18(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究思路按摘要原文分段

HCC的预后仍然很差,因为缺乏有效的治疗方法。免疫检查点抑制剂(ICIs)的应答延迟,且仅对一部分患者有效。能够在短时间内有效缩小肿瘤的治疗方法与ICIs联合使用以获得持久的肿瘤抑制效果是理想的。HCC获得了对非整倍体的耐受性增加。HCC细胞的快速分裂依赖于中心体复制。在本研究中,我们发现polo样激酶4(PLK4),一种中心体复制调节因子,代表了HCC中的一个治疗脆弱点。方法和结果:一种口服可用的PLK4抑制剂CFI-400945,通过扰乱中心体复制有效抑制了增殖中的HCC细胞。CFI-400945诱导了内复制而不停止DNA复制,导致严重的非整倍体、DNA损伤、微核形成、胞质DNA积累和衰老。胞质DNA积累引发了DEAD box解旋酶41-干扰素基因刺激因子-干扰素调节因子3/7-NF-κβ胞质DNA感知通路,从而驱动衰老相关分泌表型的转录,这些表型招募免疫细胞。CFI-400945在通过流体动力学尾静脉注射建立的肝脏特异性p53/磷酸酶和张力蛋白同源物敲除小鼠HCC模型中进行了评估。分析了肿瘤浸润的免疫细胞。CFI-400945显著阻碍了HCC生长,并增加了分化簇4阳性(CD4+)、CD8+ T细胞、巨噬细胞和NK 细胞的浸润。CFI-400945与抗程序性死亡-1的联合治疗显示出改善HCC生存的趋势。

我们发现,通过靶向中心体调节因子 PLK4 以激活胞质 DNA 传感介导的免疫应答,CFI-400945 通过抑制细胞周期和诱导抗肿瘤免疫,有效抑制了肿瘤进展,即使在晚期小鼠 HCC 中也能实现持久的抑制效果。

展开英文摘要原文

BACKGROUND AND AIMS: Prognosis of HCC remains poor due to lack of effective therapies. Immune checkpoint inhibitors (ICIs) have delayed response and are only effective in a subset of patients. Treatments that could effectively shrink the tumors within a short period of time are idealistic to be employed together with ICIs for durable tumor suppressive effects. HCC acquires increased tolerance to aneuploidy. The rapid division of HCC cells relies on centrosome duplication. In this study, we found that polo-like kinase 4 (PLK4), a centrosome duplication regulator, represents a therapeutic vulnerability in HCC. APPROACH AND RESULTS: An orally available PLK4 inhibitor, CFI-400945, potently suppressed proliferating HCC cells by perturbing centrosome duplication. CFI-400945 induced endoreplication without stopping DNA replication, causing severe aneuploidy, DNA damage, micronuclei formation, cytosolic DNA accumulation, and senescence. The cytosolic DNA accumulation elicited the DEAD box helicase 41-stimulator of interferon genes-interferon regulatory factor 3/7-NF-κβ cytosolic DNA sensing pathway, thereby driving the transcription of senescence-associated secretory phenotypes, which recruit immune cells. CFI-400945 was evaluated in liver-specific p53/phosphatase and tensin homolog knockout mouse HCC models established by hydrodynamic tail vein injection. Tumor-infiltrated immune cells were analyzed. CFI-400945 significantly impeded HCC growth and increased infiltration of cluster of differentiation 4-positive (CD4 + ), CD8 + T cells, macrophages, and natural killer cells. Combination therapy of CFI-400945 with anti-programmed death-1 showed a tendency to improve HCC survival. CONCLUSIONS: We show that by targeting a centrosome regulator, PLK4, to activate the cytosolic DNA sensing-mediated immune response, CFI-400945 effectively restrained tumor progression through cell cycle inhibition and inducing antitumor immunity to achieve a durable suppressive effect even in late-stage mouse HCC.

论文信息

作者
Chan CY、Yuen VW、Chiu DK、Goh CC、Thu KL、Cescon DW、Soria-Bretones I、Law CT
单位
Department of Pathology , The University of Hong Kong , Hong Kong SAR , China.Hong Kong
文献类型
非美国政府资助研究
期刊
Hepatology (Baltimore, Md.)2023 Mar 1
原文标识
PubMed 35302667 · DOI 10.1002/hep.32461